KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pfizer (PFE) R&D In Process (2020 - 2026)

Pfizer has reported R&D In Process over the past 9 years, most recently at $137.0 million for Q1 2026.

  • Quarterly R&D In Process rose 1422.22% to $137.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.7 billion through Mar 2026, up 6117.86% year-over-year, with the annual reading at $1.6 billion for FY2025, 1393.52% up from the prior year.
  • R&D In Process was $137.0 million for Q1 2026 at Pfizer, down from $212.0 million in the prior quarter.
  • Over five years, R&D In Process peaked at $1.4 billion in Q3 2025 and troughed at $1.0 million in Q3 2022.
  • The 5-year median for R&D In Process is $50.0 million (2023), against an average of $203.0 million.
  • Year-over-year, R&D In Process tumbled 99.54% in 2022 and then surged 10592.31% in 2025.
  • A 5-year view of R&D In Process shows it stood at $524.0 million in 2022, then crashed by 86.26% to $72.0 million in 2023, then crashed by 81.94% to $13.0 million in 2024, then surged by 1530.77% to $212.0 million in 2025, then plummeted by 35.38% to $137.0 million in 2026.
  • Per Business Quant, the three most recent readings for PFE's R&D In Process are $137.0 million (Q1 2026), $212.0 million (Q4 2025), and $1.4 billion (Q3 2025).